This article is more than 5 years old. Information may no longer be current.
Resuming warfarin after GI tract bleeding associated with lower risk for thrombosis, death
Click Here to Manage Email Alerts
Resuming warfarin therapy after an episode of gastrointestinal tract bleeding was associated with lower risk for thrombosis and death, according to a new report.
Daniel M. Witt, PharmD, FCCP, BCPS, of Kaiser Permanente of Colorado, and colleagues determined the incidence of thrombosis (stroke, systemic embolism and venous thromboembolism), recurrent gastrointestinal (GI) tract bleeding and death, as well as time until warfarin therapy was resumed during the 90 days after a GI bleeding event. Researchers used administrative and clinical databases from Kaiser Permanente Colorado in their retrospective cohort study; their analysis comprised 442 patients with a warfarin-associated index GI tract bleed, according to a press release.
“The results highlight the clinical dilemma of managing warfarin therapy following a hospitalization or ED visit for GI tract bleeding. Although we observed a numerical increase in recurrent GI tract bleeding associated with not interrupting or resuming warfarin therapy in the 90 days after the index GI tract bleeding, this increase was not statistically significant,” the researchers wrote. “However, a decision not to resume warfarin therapy was associated with a significantly increased risk of both thrombosis and death from any cause.”
Following the index bleed, 260 patients (58.8%) resumed warfarin therapy, including 41 patients whose therapy was never stopped. Median time to resume therapy was 4 days. Resuming warfarin therapy was associated with a lower risk for thrombosis (HR=0.05; 95% CI, 0.01-0.58) and lower risk for death (HR=0.31; 95% CI, 0.15-0.62).
Further, resuming therapy lowered these risks without significantly increasing the risk for recurrent GI tract bleeding (HR=1.32; 95% CI, 0.5-3.57), according to the study results. Among the 260 patients who resumed warfarin, there was one thrombotic event, 26 episodes of recurrent GI tract bleeding and 15 deaths in the 90 days after the initial GI tract bleeding event. Among the 182 patients who did not resume warfarin, there were 10 thrombotic events, 10 episodes of recurrent GI tract bleeding and 37 deaths.
“Our analysis suggests that, for many patients who have experienced GI tract bleeding, the benefits of resuming warfarin therapy will outweigh the risks. Further research will be needed to identify the optimal duration of warfarin interruption after a GI tract bleeding event and the patients for whom a more prolonged interruption can be justified,” the researchers wrote.
Disclosure: CSL Behring provided funding for the study. See the full study for additional financial disclosure information.
Collapse
Click Here to Manage Email Alerts